SCHEMBL899786

SCHEMBL899786

Cc1cc(O)c(C(C)C)cc1C(c1cc(C(C)C)c(O)cc1C)C1CC2CC1CC2c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
KMT2A Q03164 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 3/20 0.36
CYP1A2 P05177 4/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP2D6 P10635 3/20 0.36
CYP2C9 P11712 2/20 0.36
ALOX15 P16050 2/20 0.36
HIF1A Q16665 2/20 0.36
THRB P10828 1/20 0.36
PKM P14618 1/20 0.36
HSP90AA1 P07900 4/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL899712 0.82 MEN1 (0.38) KMT2AMEN1HSP90AA1
SCHEMBL898980 0.78 GABRA1 (0.41) KMT2AMEN1GAALMNACYP1A2
SCHEMBL899009 0.78 ESR1 (0.33) KMT2AMEN1TP53TRPA1
SCHEMBL899879 0.74 TRPA1 (0.39) MAPTKMT2AMEN1HTTLMNA
SCHEMBL8508897 0.73 HSD17B1 (0.33)
SCHEMBL900013 0.71 GAA (0.35) KMT2AMEN1ALDH1A1GAAHTT
SCHEMBL8509094 0.70 MEN1 (0.44) KMT2ANPSR1MEN1GAAHSD17B10
SCHEMBL899694 0.70 MEN1 (0.42) KMT2AMEN1GAALMNATHRB
SCHEMBL899819 0.68 ESR1 (0.33) KMT2AMEN1ALDH1A1GAATP53
SCHEMBL899831 0.67 MEN1 (0.38) KMT2AMEN1GAATP53TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9261781-B2 Preparation of norbornane-based PAC ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-16 US claimed
US-20130323640-A1 Preparation of Norbornane-based PAC Ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2013-12-05 US claimed
US-9261781-B2 Preparation of norbornane-based PAC ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-16 US disclosed
US-20130323640-A1 Preparation of Norbornane-based PAC Ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2013-12-05 US disclosed
US-8530133-B2 Preparation of norbornane-based PAC ballasts PROMERUS, LLC (US) 2013-09-10 US disclosed
EP-2622410-A1 NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC Promerus, LLC (US) 2013-08-07 EP disclosed
US-20120135352-A1 Preparation of Norbornane-based PAC Ballasts PROMERUS LLC (US) 2012-05-31 US disclosed
WO-2012044719-A1 NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC PROMERUS LLC (US) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135352-A1 Preparation of Norbornane-based PAC Ballasts NBAS, PHB2, BDNF MAPT 923/4885KMT2A 701/4885NPSR1 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.